BridgeMD
New treatment option for Alcohol Use Disorder
Official title StuDy AimED at Increasing AlCohol AbsTinEnce
ClinicalTrials.gov ID: NCT05778734
What this study is testing
- What it's testing
- The goal of this clinical trial is to test the feasibility \& acceptability of an integrated CM-PST intervention (in K99 phase) and preliminary efficacy (in R00 phase), vs. CM alone, to improve treatment efficacy and inform about neural mechanisms of treatment effects in young adults with Alcohol Use Disorder (AUD).
- Time commitment: about 12 weeks
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 24. Healthy volunteers may be eligible.
You may be able to join if
- Male and female young adults aged 18-24 yr
- English-speaking
- Current alcohol use greater or equal to 1 day/week via phone screening, and meet criteria for (past year) mild, moderate or severe AUD on the AUDIT...
- Completion of written informed consent
- Baseline screening study visit.
You likely can't join if
- Participation in past 6 mo. in AUD or substance use treatment
- Current use of medications used to treat AUD (e.g., naltrexone)
- Lifetime DSM-5 diagnosis of schizophrenia, bipolar disorder, or any psychotic disorder.
- Current use of psychoactive drugs, determined by positive drug toxicology screen
- Conditions (e.g., tic disorder) that would interfere with psychophysiological indices of reward functioning
- Pregnancy or intention to become pregnant
See the full eligibility criteria
- Male and female young adults aged 18-24 yr
- English-speaking
- Current alcohol use greater or equal to 1 day/week via phone screening, and meet criteria for (past year) mild, moderate or severe AUD on the AUDIT and AUDADIS surveys.
- Completion of written informed consent
- Baseline screening study visit.
- Participation in past 6 mo. in AUD or substance use treatment
- Current use of medications used to treat AUD (e.g., naltrexone)
- Lifetime DSM-5 diagnosis of schizophrenia, bipolar disorder, or any psychotic disorder.
- Current use of psychoactive drugs, determined by positive drug toxicology screen
- Conditions (e.g., tic disorder) that would interfere with psychophysiological indices of reward functioning
- Pregnancy or intention to become pregnant
- Additional exclusion criteria pertaining to fMRI scan in R00 phase only: a) bodily ferrous metals (e.g., aneurysm clips, shrapnel/retained particles) or b) claustrophobia, inability to tolerate small enclosed spaces.
The study team makes the final eligibility decision.
Where it's taking place
- Chicago, Illinois, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 12 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 24 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Chicago, Illinois, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.